Document:

Exhibit 4.3

 

FIRST AMENDMENT TO

WARRANT NO. 1

 

This First Amendment
to Warrant No. 1 (“First Amendment”) is entered into as of the 9th day of October, 2013 by Edge Therapeutics, Inc.
(“Company”) and the New Jersey Economic Development Authority (“Holder”), hereinafter, collectively referred
to as “Parties”.

 

WHEREAS, Company executed
and delivered to Holder that certain Warrant No. 1, dated May 3, 2010 (the “Original Warrant”) to subscribe for and
purchase of 16,667 shares (the “Original Warrant Shares”) of the fully paid and nonassessable capital stock, “no”
par value, of the Company, at a purchase strike price equal to $3.00 per share (“Original Warrant Price”) in conjunction
with a certain $100,000 loan made by the Holder to Company (the “Loan”). The Loan is evidenced by a Convertible Promissory
Note of the same date (the “Original Note”). Capitalized terms used but not defined herein shall have the meaning ascribed
to them in the Original Warrant and other Transaction Documents; and

 

WHEREAS, on April 12,
2011, the Company filed a First Amended and Restated Certificate of Incorporation memorializing that each one (1) share of existing
Common Stock and Preferred Stock, par value $0.001, was automatically reclassified and combined into three (3) fully paid and non-assessable
shares of Common Stock and Preferred Stock, respectively, par value $0.00033 (the “3-for-1 Stock Split”); and

 

WHEREAS, based on the
3-for-1 Stock Split, Company requested and Holder agreed to increase the number of Original Warrant Shares from 16,667 to 50,001
and decrease the Original Warrant Price from $3.00 to $1.00; and

 

WHEREAS, it is, therefore,
necessary to amend the Original Warrant, retroactively beginning April 12, 2011 for documentation purpose only, from a grant of
16,667 shares of capital stocks of the Company, at a purchase strike price equal to $3.00 per share to a grant of 50,001 shares
of common stocks of the Company, at a purchase strike price equal to $1.00 per share.

 

NOW THEREFORE, in consideration
of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereby agree as follows:

 

1.                 
Lines 12 and 13 on page 1, cover page of the Original Warrant is modified by deleting “16,667 SHARES OF CAPITAL STOCK”
and replacing it with “50,001 SHARES OF COMMON STOCK”.

 

2.                 
First sentence of the first paragraph on page 1, caver page of the Original Warrant is deleted in its entirety and replaced
with:

 

    	 

    	 

    

“FOR VALUE RECEIVED,
EDGE THERAPEUTICS, INC., having an address at 139 South Street, Suite 102, New Providence, NJ 07974, a Delaware corporation (the
“Company”), hereby certifies that THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY, or its registered transferees,
successors or assigns (each person or entity holding all or part of this Warrant being referred to as a “Holder”),
is the registered holder of the warrant (the “Warrant”) to subscribe for and purchase 50,001 shares (the “Warrant
Shares”) of the fully paid and nonassessable common stock, “no” par value, of the Company, at a purchase
strike price equal to $1.00 per share (the “Warrant Price”), on or before, 5:00 P.M., Eastern Time, on 10 years
from Warrant Date (the “Expiration Date”), subject to the provisions and upon the terms and conditions hereinafter
set forth; provided, however, that in the event that any portion of this Warrant is unexercised as of the Expiration
Date, the terms of Section 2.3 below shall apply. As used in this Warrant, the term “Business Day” means
any day other than a Saturday or Sunday on which commercial banks located in New Jersey are open for the general transaction of
business. This Warrant is issued in connection with, and is subject to, that certain Convertible Loan Agreement, of even date herewith,
by and between the Company and the Holder (the “Loan Agreement”), and the terms and conditions of the Loan Agreement
are incorporated herein as though set forth at length. This Warrant may be exercised at any time on or before 5:00 pm eastern standard
time on Expiration Date.”

 

3.                 
Except as otherwise provided in this First Amendment, all of the terms, covenants and conditions of the Original Warrant
shall remain in full force and effect.

 

4.                 
All references to the term “Warrant” and “Transaction Documents” in the Original Warrant and the
other Transaction Documents shall be deemed to refer to the Original Warrant, as modified by this First Amendment.

 

5.                 
This First Amendment may be executed in multiple counterparts, each of which, when so executed, shall be deemed an original,
and all of which shall together constitute one and the same document, and shall be binding on the signatories.

 

[SIGNATURE PAGE FOLLOWS]

 

    	2

    	 

    

IN WITNESS WHEREOF,
the Parties have caused this First Amendment to be executed on their behalf by one of their officers thereunto duly authorized.

 

	WITNESS:	 	EDGE THERAPEUTICS, INC.
	 	 	 	 
	 	 	 	 
	 	 	 	 
	/s/ Albert N. Marchio, II		By:	/s/ Brian A. Leuthner
	 	 	Name:	Brian A. Leuthner
	 	 	Title:	President and Chief Executive Officer
	 	 	 	 
	 	 	 	 
	 	 	Accepted and Agreed:

NEW JERSEY ECONOMIC DEVLEOPMENT 

AUTHORITY
	 	 	 
	 	 	 
	 	 	By: 	/s/ Kathleen Coviello
	 	 	Name: 	Kathleen Coviello
	 	 	Title:   	Director-Technology & Life Sciences

    	3Exhibit 4.4

 

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN
CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF.  NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE SECURITIES ACT OF 1933. THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE
TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE PURCHASER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

 

EDGE THERAPEUTICS, INC.

 

WARRANT TO PURCHASE [______] SHARES OF

COMMON STOCK

 

	DATE:      [___________], 2012	Warrant No. [__]

FOR VALUE
RECEIVED, EDGE THERAPEUTICS, Inc., having an address at 139 South Street, Suite
102, New Providence, New Jersey 07974, a Delaware corporation (the “Company”), hereby certifies that [_______________________________],
or its registered transferees, successors or assigns (each person or entity holding all or part of this Warrant being referred
to as a “Holder”), is the registered holder of the warrant (the “Warrant”) to subscribe
for and purchase [_________] shares (the “Warrant Shares”) of the fully paid and nonassessable Common Stock,
$0.00033 par value of the Company (the “Common Stock”), at a purchase price per share equal to $1.75 per share,
as adjusted from time to time as provided in Article 3 (the “Exercise Price”), at any time and
from time to time on and after the date hereof (the “Warrant Date”) and through and including 5:00 P.M., Eastern
Time, on [___________], 2017 (the “Expiration Date”), subject to the provisions and upon the terms and conditions
hereinafter set forth. As used in this Warrant, the term “Business Day” means any day other than a Saturday
or Sunday on which commercial banks located in New Jersey are open for the general transaction of business. This Warrant is one
of a series of similar warrants, and is issued in connection with, and is subject to, that certain Securities Purchase Agreement,
dated the Warrant Date, by and between the Company and the purchasers identified therein (the “Securities Purchase Agreement”).

 

Article 1.               
Exercise.

 

1.1              
Method of Exercise; Payment; Issuance of New Warrant.

 

(a)               
Subject to the provisions hereof, the Holder may exercise this Warrant, in whole or part and from time to time, by the surrender
of this Warrant (together with the Notice of Exercise attached hereto as Appendix A duly executed and payment of the Exercise
Price for the number of Warrant Shares as to which the Warrant is being exercised, or in the event of a cashless exercise pursuant
to Section 1.2 below, together with the Net Issue Election Notice attached hereto as Appendix B, duly executed and
completed) at the principal office of the Company, or such other office or agency of the Company as it may reasonably designate
by written notice to the Holder, during normal business hours on any Business Day (the date of surrender may hereinafter be referred
to as an “Exercise Date”).

 

    	 

    	 

    

(b)               
On the Exercise Date the Holder shall deliver to the Company payment by the Holder in cash, certified check payable to the
Company or wire transfer of immediately available funds to an account designated to the Holder by the Company of an amount equal
to the Exercise Price multiplied by the number of Warrant Shares then being purchased, unless the exercise is subject to Section
1.2. The Holder (or such other person or persons as directed by the Holder) shall be treated for all purposes as the holder
of record of such Warrant Shares as of the close of business on the date on which the Holder shall have delivered such payment
to the Company, unless the exercise is pursuant to Section 1.2.

 

(c)               
In the event of any exercise of the rights represented by this Warrant, certificates for the whole number of shares of Common
Stock so purchased shall be delivered to the Holder (or such other person or persons as directed by the Holder) as promptly as
is reasonably practicable, but not later than five (5) Business Days, after the applicable Exercise Date, at the Company’s
expense, and, unless this Warrant has been fully exercised, a new Warrant (in the same form as this Warrant) representing the unexercised
portion of this Warrant, shall also be issued to the Holder as soon as reasonably practicable thereafter, but not later than five
(5) Business Days, after the applicable Exercise Date.

 

1.2              
Cashless Right to Convert Warrant into Stock. In addition to and without limiting the rights of the Holder hereof under
the terms of this Warrant, the Holder may elect to receive, without the payment by the Holder of the Exercise Price, Warrant Shares
equal to the value of this Warrant or any portion hereof by the surrender of this Warrant (or such portion of this Warrant being
so exercised) together with the Net Issue Election Notice annexed hereto as Appendix B duly executed and completed, at the
office of the Company, or such other office or agency of the Company as it may reasonably designate by written notice to the Holder,
during normal business hours on any Business Day. With respect to Warrant Shares of capital stock issuable to the Holder upon an
exercise pursuant to this Section 1.2, the Holder (or such other person or persons as directed by the Holder) shall be treated
for all purposes as the holder of record of such Warrant Shares as of the close of business on the applicable Exercise Date. The
Company shall issue to the Holder such number of fully paid, validly issued and nonassessable Warrant Shares, as is computed using
the following formula:

 

X = Y * (A-B)

    A

    where

 

where

 

	 	X = 	the number of shares to be issued to the Holder pursuant to this Article 1.
	 	 	 
	 	Y = 	the number of shares covered by this Warrant in respect of which the net issue election is made pursuant to this Article 1.
	 	 	 
	 	A =	the average of the Closing Sales Prices for the ten (10) consecutive trading days ending on the date immediately preceding the date the net issue election is made pursuant to this Article 1.   

    	2

    	 

    

	 	 	For purposes of this Warrant, “Closing Sale Price” means, for any security as of any date, the last trade price for such security on the principal trading market (whichever of the New York Stock Exchange, the NYSE Amex Equities (formerly the American Stock Exchange), the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or the OTC Bulletin Board on which the Common Stock is primarily listed or quoted for trading on the date in question) for such security, or, if no last trade price is reported for such security, the average of the bid and ask prices, of any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC.  If the Closing Sale Price cannot be calculated for a security on a particular date, the Closing Sale Price of such security on such date shall be the fair market value as the Board of Directors of the Company in its good faith judgment so determines.  The Board of Directors’ determination shall be binding upon all parties absent demonstrable error.  All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period
	 	 	 
	 	B = 	the Exercise Price in effect under this Warrant at the time the net issue election is made pursuant to this Article 1. 

Article 2.               
Reservation of Shares; Stock Fully Paid; Listing.
The Company shall keep reserved a sufficient number of shares of the authorized and unissued shares of Common Stock, to provide
for the exercise of the rights of purchase represented by this Warrant in compliance with its terms. All Warrant Shares issued
upon exercise of this Warrant shall be, at the time of delivery of the certificates for such Warrant Shares upon payment in full
of the Exercise Price therefor in accordance with the terms of this Warrant (or proper exercise of the cashless exercise rights
contained in Section 1.2 hereof), duly authorized, validly issued, fully paid and non-assessable shares of Common Stock
of the Company. The Company shall during all times prior to the Expiration Date when the shares of Common Stock issuable upon the
exercise of this Warrant are authorized for quotation on Nasdaq or listing on the New York Stock Exchange (or authorized for listing
or quotation on any other national securities exchange or the Over-the-Counter Bulletin Board or the “pink sheets”,
as the case may be), keep the shares of Common Stock issuable upon the exercise of this Warrant authorized for quotation on Nasdaq
or listing on the New York Stock Exchange (or authorized for listing or quotation on any other national securities exchange or
the Over-the-Counter Bulletin Board or the “pink sheets”, as the case may be).

 

Article 3.               
Adjustments and Distributions. The number and kind of securities purchasable upon the
exercise of this Warrant shall be subject to adjustment from time to time upon the occurrence of certain events, as follows:

 

3.1              
Splits, Dividends and Subdivisions. If the Company shall at any time or from time to time while this Warrant is outstanding,
pay a dividend or make a distribution on its Common Stock in shares of Common Stock, subdivide its outstanding shares of Common
Stock into a greater number of shares or combine its outstanding shares of Common Stock into a smaller number of shares, then the
number of Warrant Shares purchasable upon exercise of this Warrant in effect immediately prior to the date upon which such change
shall become effective shall be proportionally adjusted by the Company so that the Holder thereafter exercising this Warrant shall
be entitled to receive the number of shares of Common Stock or other Common Stock which the Holder would have received if this
Warrant had been fully exercised immediately prior to such event. Such adjustments shall be made successively whenever any event
listed above shall occur.

 

    	3

    	 

    

3.2              
Recapitalization, reclassification or reorganization. If any recapitalization, reclassification or reorganization of the
Common Stock of the Company (other than a change in par value or a subdivision or combination as provided for in Section 3.1
above) shall be effected in such a manner (including, without limitation, in connection with a consolidation or merger in which
the Company is the continuing corporation), that holders of Common Stock shall be entitled to receive stock, securities, or other
assets or property (a “Reorganization”), then, as a condition of such Reorganization, lawful and adequate provisions
shall be made by the Company whereby the Holder hereof shall thereafter have the right to purchase and receive upon exercise hereof
(in lieu of the shares of the Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise
of the rights represented hereby) such shares of stock, securities or other assets or property as may be issued or payable with
respect to or in exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such Common
Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby. In the event of any
Reorganization, appropriate provision shall be made by the Company with respect to the rights and interests of the Holder of this
Warrant to the end that the provisions hereof (including, without limitation, provisions for adjustments of the Exercise Price
and of the number of Warrant Shares) shall thereafter be applicable, in relation to any shares of stock, securities or assets thereafter
deliverable upon the exercise hereof. The provisions of this Section 3.2 shall similarly apply to successive Reorganizations.

 

3.3              
Merger, Consolidation or Sale of Assets. If any consolidation or merger of the Company with another entity in which the
Company is not the survivor, or sale, transfer or other disposition of all or substantially all of the Company’s assets to
another entity shall be effected, then, as a condition of such consolidation, merger, sale, transfer or other disposition, lawful
and adequate provision shall be made whereby the Holder shall thereafter have the right to purchase and receive upon the basis
and upon the terms and conditions herein specified and in lieu of the Warrant Shares immediately theretofore issuable upon exercise
of this Warrant, such shares of stock, securities, cash or assets as would have been issuable or payable with respect to or in
exchange for a number of Warrant Shares equal to the number of Warrant Shares immediately theretofore issuable upon exercise of
this Warrant, had such consolidation, merger, sale, transfer or other disposition not taken place, and in any such case appropriate
provision shall be made with respect to the rights and interests of each Holder to the end that the provisions hereof (including,
without limitation, provision for adjustment of the Exercise Price and of the number of Warrant Shares) shall thereafter be applicable,
as nearly equivalent as may be practicable in relation to any shares of stock, securities, cash or properties thereafter deliverable
upon the exercise thereof. The Company shall not effect any such consolidation, merger, sale, transfer or other disposition unless
prior to or simultaneously with the consummation thereof the successor entity (if other than the Company) resulting from such consolidation
or merger, or the entity purchasing or otherwise acquiring such assets or other appropriate entity shall assume the obligation
to deliver to the Holder such shares of stock, securities, cash or assets as, in accordance with the foregoing provisions, such
Holder may be entitled to purchase, and the other obligations under this Warrant. The provisions of this Section 3.3 shall
similarly apply to successive consolidations, mergers, sales, transfers or other dispositions.

 

3.4              
Distributions. In case the Company shall fix a payment date for the making of a distribution to all holders of Common Stock
of evidences of indebtedness or assets (other than dividends or distributions referred to in Section 3.1 hereof), or subscription
rights or warrants, the Holder shall be entitled to receive upon exercise hereof, simultaneous with the holders of Common Stock,
said assets or evidences of indebtedness so distributed, or of such subscription rights or warrants, that the Holder would have
received if this Warrant had been fully exercised immediately prior to such event. In the event that the Company implements a shareholder
rights plan, such rights plan shall provide that upon exercise of this Warrant the Holder will receive, in addition to the Common
Stock issuable upon such exercise, the rights issued under such rights plan (as if the Holder had exercised this Warrant prior
to implementing the rights plan and notwithstanding the occurrence of an event causing such rights to separate from the Common
Stock at or prior to the time of exercise). Any distribution of rights or warrants pursuant to a shareholder rights plan complying
with the requirements set forth in the immediately preceding sentence of this paragraph shall not constitute a distribution of
rights or warrants for the purposes of this Section 3.4.

 

    	4

    	 

    

3.5              
Other Securities. In the event that, as a result of an adjustment made pursuant to this Article 3, the Holder shall
become entitled to receive any shares of capital stock of the Company other than shares of Common Stock, the number of such other
shares so receivable upon exercise of this Warrant shall be subject thereafter to adjustment from time to time in a manner and
on terms as nearly equivalent as practicable to the provisions with respect to the Warrant Shares contained in this Warrant.

 

3.6              
Notice of Adjustments. With each adjustment pursuant to this Article 3, the Company shall deliver a certificate signed
by its chief financial or executive officer setting forth, in reasonable detail, the event requiring the adjustment, the amount
of the adjustment, the method by which such adjustment was calculated, the Exercise Price and the number of Warrant Shares purchasable
hereunder after giving effect to such adjustment, which shall be mailed by first class mail, postage prepaid to the Holder.

 

Article 4.               
Transfer Taxes. The Company will pay any documentary stamp taxes attributable to the initial
issuance of Warrant Shares issuable upon the exercise of the Warrant; provided, however, that the Company shall not be required
to pay any tax or taxes which may be payable in respect of any transfer involved in the issuance or delivery of any certificates
for Warrant Shares in a name other than that of the registered holder of this Warrant in respect of which such shares are issued,
and in such case, the Company shall not be required to issue or deliver any certificate for Warrant Shares or any Warrant until
the person requesting the same has paid to the Company the amount of such tax or has established to the Company’s reasonable
satisfaction that such tax has been paid.

 

Article 5.               
Mutilated or Missing Warrants. In case this Warrant shall be mutilated, lost, stolen,
or destroyed, the Company shall issue in exchange and substitution of and upon cancellation of the mutilated Warrant, or in lieu
of and substitution for the Warrant lost, stolen or destroyed, a new Warrant of like tenor and for the purchase of a like number
of Warrant Shares, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction
of the Warrant, and with respect to a lost, stolen or destroyed Warrant, reasonable assurance or bond with respect thereto, if
requested by the Company.

 

Article 6.               
Fractional Shares. No fractional shares of Common Stock shall be issued in connection
with any exercise or cashless exercise hereunder, and in lieu of any such fractional shares the Company shall make a cash payment
therefor to the Holder (or such other person or persons as directed by the Holder) based on the Fair Market Value of a share of
Common Stock on the date of exercise or cashless exercise of this Warrant.

 

Article 7.               
Compliance with Securities Act and Legends. The Holder, by acceptance hereof,
agrees that this Warrant and the shares of Common Stock to be issued upon exercise hereof, are being acquired for investment and
that such Holder will not offer, sell or otherwise dispose of this Warrant, or any shares of Common Stock to be issued upon exercise
hereof except under circumstances which will not result in a violation of the Securities Act of 1933, as amended, or the rules
and regulations promulgated thereunder, as amended (the “Securities Act”), or any state’s securities
laws. Upon exercise of this Warrant, the Holder shall confirm in writing, by executing the form attached as Schedule 1
to Appendix A hereto, that the shares of Common Stock so purchased are being acquired for investment and not with a view
toward distribution or resale. All shares of Common Stock issued upon exercise of this Warrant (unless registered under the Securities
Act) shall be stamped or imprinted with the legends required by applicable state and federal securities laws in the opinion of
counsel to the Company.

 

    	5

    	 

    

Article 8.               
Rights as Stockholders; Information. Except as expressly provided in this Warrant or the
Securities Purchase Agreement, no Holder, as such, shall be entitled to vote or receive dividends or be deemed the holder of Common
Stock or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall
anything contained herein be construed to confer upon the Holder, as such, any of the rights of a stockholder of the Company or
any right to vote for the election of the directors or upon any matter submitted to stockholders at any meeting thereof, or to
receive notice of meetings, or to receive dividends or subscription rights or otherwise, until this Warrant shall have been exercised
and the Warrant Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 

 

Article 9.               
Modification and Waiver. This Warrant and any provision hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the Company and the holders of Warrants representing no less
than a majority of the Warrant Shares obtainable upon exercise of the Warrants then outstanding. Such change, waiver, discharge
or termination shall be binding on all future Holders.

 

Article 10.           
Notices. All notices, requests, consents and other communications hereunder shall be in
writing, shall be addressed to the receiving party's address set forth below or to such other address as a party may designate
by notice hereunder, and shall be either (i) delivered by hand, (ii) made by facsimile, (iii) sent by a recognized
overnight courier, or (iv) sent by certified mail, return receipt requested, postage prepaid.

 

If to Holder, at the address
set forth on the signature page to the Securities Purchase Agreement.

 

If to the Company, at the address
set forth above, to the attention of the President;

 

or to such other address as any party hereto
shall notify the other parties hereto (as provided above) from time to time.

 

Article 11.           
All notices, requests, consents and other communications hereunder shall be deemed to
have been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party
set forth above, (ii) if made by facsimile, at the time that receipt thereof has been acknowledged by electronic confirmation
or otherwise, (iii) if sent by overnight courier, on the next Business Day following the day such notice is delivered to the
courier service, or (iv) if sent by registered or certified mail, on the fifth (5th) Business Day following the day
such mailing is made.

 

Article 12.           
Descriptive Headings. The descriptive headings contained in this Warrant are inserted
for convenience only and do not constitute a part of this Warrant.

 

Article 13.           
Governing Law; Consent to Jurisdiction. This Warrant shall be governed by, and
construed in accordance with, the internal laws of the State of New Jersey, without reference to the choice of law principles thereof.
Any legal action, suit or proceeding arising out of or relating to this Warrant, or the transactions contemplated hereby, shall
only be instituted, heard and adjudicated (excluding appeals) in a state or federal court located in the State of New Jersey, and
each party hereto knowingly, voluntarily and intentionally waives any objection which such party may now or hereafter have to the
laying of the venue of any such action, suit or proceeding, and irrevocably submits to the exclusive personal jurisdiction of any
such court in any such action, suit or proceeding. Service of process in connection with any such action, suit or proceeding may
be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this
Warrant except as otherwise required by law. Notwithstanding the foregoing to the contrary, the Holder may institute and prosecute
any action, suit or proceeding in any court of competent jurisdiction it shall deem advisable in connection the enforcement of
its rights hereunder.

 

    	6

    	 

    

Article 14.           
Waiver of Jury Trial. Each party acknowledges and agrees that any controversy which may
arise under this Warrant is likely to involve complicated and difficult issues. Accordingly,  each
such party hereby KNOWINGLY, VOLUNTARILY AND INTENTIONALLY irrevocably and unconditionally waives any right such party may have
to a trial by jury in respect to any litigation directly or indirectly arising out of or relating to this WARRANT or the transactions
contemplated HEREby.  Each party certifies and acknowledges that (i) no other party has represented, expressly or otherwise,
that such other party would not, in the event of litigation, seek to enforce the foregoing waiver, (ii) each such party understands
and has considered the implications of this waiver, and (iii) each such party has been induced to enter into this Warrant by, among
other things, the waivers and certifications in this Article 14.

 

Article 15.           
Acceptance. Receipt of this Warrant by the Holder hereof shall constitute acceptance of
and agreement to the foregoing terms and conditions.

 

Article 16.           
No Impairment of Rights. The Company shall not, by amendment of its Certificate of Incorporation
or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will
at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary
or appropriate in order to protect the rights of the holder of this Warrant against material impairment.

 

Article 17.           
Assignment. A Holder may transfer its rights hereunder, in whole or in part, to any other
Person provided that written notice is given to the Company of any such transfer and such transfer is in accordance with Section
4(1) of the Securities Act or another valid exemption from the registration requirements of Section 5 of the Securities Act, and
in accordance with all applicable securities laws of the states of the United States. Upon receipt by the Company of notice by
a Holder of a transfer of any portion of this Warrant, the Company shall promptly deliver to a transferee a Warrant in the form
hereof exercisable for the number of Warrant Shares the right of which to purchase has been transferred. 

 

Article 18.           
Severability. In the event that any court of competent jurisdiction shall determine that
any provision, or any portion thereof, contained in this Warrant shall be unenforceable in any respect, then such provision shall
be deemed limited to the extent that such court deems it enforceable, and as so limited shall remain in full force and effect.
In the event that such court shall deem any such provision, or portion thereof wholly unenforceable, the remaining provisions of
this Warrant shall nevertheless remain in full force and effect.

 

* * * * *

 

[Signature Pages Follow]

 

    	7

    	 

    

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed on its behalf by one of its officers thereunto duly authorized.

 

	 	COMPANY:
	 	EDGE THERAPEUTICS, INC.
	 	 	 
	 	 	 
	 	By: _______________________________
	 	Name: 	Brian A. Leuthner
	 	Title:   	President and CEO
	 	Dated: 	___________, 2012

    	 

    	 

    

APPENDIX A

 

NOTICE OF EXERCISE

 

To:        Edge Therapeutics, Inc. (“Company”)

 

1.           The undersigned hereby elects to
purchase ____ of the outstanding shares of Common Stock of COMPANY pursuant to the terms of the attached Warrant.

 

2.           Please issue a certificate or certificates
representing said shares in the name of the undersigned or in such other name or names as are specified below:

 

[___________________]

 

[Address]

 

	By:  _________________________
	Name: 	______________________
	Title: 	______________________
	Date: 	______________________

3.           Please issue a new Warrant of equivalent
form and tenor for the unexercised portion of the attached Warrant in the name of the undersigned or in such other name as is specified
below:

 

[_____________________________________]

 

	By:   _________________________
	Name: 	______________________
	Title: 	______________________
	Date: 	______________________

    	 

    	 

    

SCHEDULE 1

 

INVESTMENT REPRESENTATION STATEMENT

 

	Purchaser:	[_________________________]
	Company:	Edge Therapeutics, Inc.
	Security: 	Common Stock
	Amount:	_____________________________
	Date:	_____________________________

In connection with the purchase of the
above-listed securities (the “Securities”), the undersigned (the “Purchaser”) represents
to the Company as follows:

 

(a)The Purchaser is aware of the Company's
business affairs and financial condition, and has acquired sufficient information about the Company to reach an informed and knowledgeable
decision to acquire the Securities. The Purchaser is purchasing the Securities for its own account for investment purposes only
and not with a view to, or for the resale in connection with, any “distribution” thereof for purposes of the Securities
Act of 1933, as amended (the “Securities Act”).

 

(b)The Purchaser understands that the
Securities have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends
upon, among other things, the bona fide nature of the Purchaser's investment intent as expressed herein. In this connection, the
Purchaser understands that, in the view of the Securities and Exchange Commission (“SEC”), the statutory basis
for such exemption may be unavailable if the Purchaser's representation was predicated solely upon a present intention to hold
these Securities for the minimum capital gains period specified under applicable tax laws, for a deferred sale, for or until an
increase or decrease in the market price of the Securities, or for a period of one year or any other fixed period in the future.

 

(c)The Purchaser further understands
that the Securities must be held indefinitely unless subsequently registered under the Securities Act or unless an exemption from
registration is otherwise available. In addition, the Purchaser understands that the certificate evidencing the Securities will
be imprinted with the legend referred to in the Warrant under which the Securities are being purchased.

 

(d)The Purchaser is aware of the provisions
of Rule 144 and 144A, promulgated under the Securities Act, which, in substance, permit limited public resale of “restricted
securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate of such issuer), in a non-public
offering subject to the satisfaction of certain conditions, if applicable, including, among other things: The availability of certain
public information about the Company, the resale occurring not less than six (6) months after the party has purchased and paid
for the securities to be sold; the sale being made through a broker in an unsolicited “broker's transaction” or in
transactions directly with a market maker (as said term is defined under the Securities Exchange Act of 1934, as amended) and the
amount of securities being sold during any three-month period not exceeding the specified limitations stated therein.

 

(e)The Purchaser further understands
that at the time it wishes to sell the Securities there may be no public market upon which to make such a sale, and that, even
if such a public market then exists, the Company may not be satisfying the current public information requirements of Rule 144
and 144A, and that, in such event, the Purchaser may be precluded from selling the Securities under Rule 144 and 144A even if the
six-month minimum holding period had been satisfied.

 

    	 

    	 

    

(f)The Purchaser further understands
that in the event all of the requirements of Rule 144 and 144A are not satisfied, registration under the Securities Act, compliance
with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rule 144 is not
exclusive, the Staff of the SEC has expressed its opinion that persons proposing to sell private placement securities other than
in a registered offering and otherwise than pursuant to Rule 144 will have a substantial burden or proof in establishing that an
exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate
in such transactions do so at their own risk.

 

	 	[_______________________________]
	 	 	 
	 	 	 
	 	By: _________________________________
	 	Name: 	_____________________________
	 	Title:  	_____________________________

    	 

    	 

    

APPENDIX B

 

NET ISSUE ELECTION NOTICE

 

To: Edge Therapeutics, Inc.

 

Date: ______________________

 

The undersigned hereby
elects under Section 1.2 of this Warrant to surrender the right to purchase ____________ of the outstanding shares of Common
Stock pursuant to this Warrant and hereby requests the issuance of such shares of Common Stock. The certificate(s) for the shares
issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated below.

 

_____________________________________

Signature

 

[________________________________]

Name for Registration

 

[Address]

Attn: [__________________]

Mailing Address

 

[Address]

Attn: [__________________]

Mailing Address

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]